Skip to main content

Breadcrumb

  1. Home

Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

American Registry of Pathology Expert Opinions

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about American Registry of Pathology Expert Opinions

Predictive Markers Require Thorough Analytic Validation

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Predictive Markers Require Thorough Analytic Validation

Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx

EBV–Associated Lymphoproliferative Disorders: Update in Classification

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about EBV–Associated Lymphoproliferative Disorders: Update in Classification

The ever-changing world of gene fusions in cancer: a secondary gene fusion and progression

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about The ever-changing world of gene fusions in cancer: a secondary gene fusion and progression

Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 79
  • Page 80
  • Page 81
  • Page 82
  • Page 83
  • Page 84
  • Page 85
  • Page 86
  • Page 87
  • …
  • Next page Next
  • Last page Last
Subscribe to